Impact of stable PGI 2 analog iloprost on early graft viability after liver transplantation: A pilot study

Clinical Transplantation

Volumn 26, Issue 1, 2012, Pages

  Bärthel, Erik ^a   Rauchfuß, Falk ^a   Hoyer, Heike ^a   Habrecht, Olaf ^a   Jandt, Karin ^a   Götz, Max ^a   Voigt, Rigo ^a   Heise, Michael ^a   Marx, Gernot ^a,b   Settmacher, Utz ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Initial non function; Ischemia reperfusion injury; Liver transplantation; Primary dysfunction; Prostaglandins

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ILOPROST;

ACUTE KIDNEY FAILURE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGRAFT; ANASTOMOSIS LEAKAGE; ANASTOMOSIS STENOSIS; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHOLANGITIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GASTROINTESTINAL DISEASE; GRAFT PATENCY; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; INCIDENCE; LIVER TRANSPLANTATION; LIVER VEIN THROMBOSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; PERITONITIS; PILOT STUDY; PLEURA EFFUSION; PNEUMONIA; POSTOPERATIVE HEMORRHAGE; PRIMARY GRAFT DYSFUNCTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; RESPIRATORY FAILURE; SAFETY; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; EPOPROSTENOL; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; ILOPROST; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; PROSPECTIVE STUDIES; REPERFUSION INJURY; TRANSPLANTATION, HOMOLOGOUS; VASODILATOR AGENTS; YOUNG ADULT;

EID: 84856668652     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2011.01516.x     Document Type: Article

References (56)

1. Ploeg RJ, D'Alessandro AM, Hoffmann RM et al. Impact of donor factors and preservation on function and survival after liver transplantation. Transplant Proc 1993: 25: 3031.
2. Deschenes M, Belle SH, Krom RA, Zetterman RK, Lake JR. Early allograft dysfunction after liver transplantation: a definition and predictors of outcome. National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Transplantation 1998: 66: 302.
3. Schemmer P, Nickkholgh A, Hinz U et al. Extended donor criteria have no negative impact on early outcome after liver transplantation: a single-center multivariate analysis. Transpl Proc 2007: 39: 529.
4. S.R. Johnson SAMCDWH. Primary nonfunction (PNF) in the MELD era: an SRTR database analysis. Am J Transplant 2007;7:1003.
5. Fondevila C, Busuttil RW, Kupiec-Weglinski JW. Hepatic ischemia/reperfusion injury - a fresh look. Exp Mol Pathol 2003: 74: 86.
6. Tauber S, Menger MD, Lehr H-A. Microvascular in vivo assessment of reperfusion injury: significance of prostaglandin E1 and I2 in postischemic "no-reflow" and "reflow-paradox." J Surg Res 2004: 120: 1.
7. Totsuka E, Todo S, Zhu Y et al. Attenuation of ischemic liver injury by prostaglandin E1 analogue, misoprostol, and prostaglandin I2 analogue, OP-41483. J Am Coll Surg 1998: 187: 276.
8. Neumann U, Kaisers U, Langrehr J et al. Reduction of reperfusion injury with prostacyclin I2 after liver transplantation. Transplant Proc 1999: 31:1029.
9. Kornberg A, Schotte U, Kupper B, Hommann M, Scheele J. Impact of selective prostaglandin E1 treatment on graft perfusion and function after liver transplantation. Hepatogastroenterology 2004: 51: 526.
10. Greig PD, Woolf GM, Abecassis M et al. Treatment of primary liver graft non-function with prostaglandin E1 results in increased graft and patient survival. Transplant Proc 1989;21(1 Pt 2):2385.
11. Gedik E, Girgin S, Obay BD, Ozturk H, Buyukbayram H. Iloprost, a prostacyclin (PGI2) analogue, reduces liver injury in hepatic ischemia-reperfusion in rats. Acta Cir Bras 2009: 24: 226.
12. Natori S, Fujii Y, Kurosawa H, Nakano A, Shimada H. Prostaglandin E1 protects against ischemia-reperfusion injury of the liver by inhibition of neutrophil adherence to endothelial cells. Transplantation 1997: 64: 1514.
13. Whittle BJ, Moncada S, Vane JR. Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. Prostaglandins. 1978: 16: 373.
14. Zhou W, Hashimoto K, Goleniewska K et al. Prostaglandin I2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells. J Immunol 2007: 178: 702.
15. Zhou W, Blackwell T, Goleniewska K et al. Prostaglandin I2 analogs inhibit Th1 and Th2 effector cytokine production by CD4 T cells. J Leukoc Biol 2007: 81: 809.
16. Neumann UP, Kaisers U, Langrehr JM et al. Administration of prostacyclin after liver transplantation: a placebo controlled randomized trial. Clin Transplant 2000: 14: 70.
17. Klein AS, Cofer JB, Pruett TL et al. Prostaglandin E1 administration following orthotopic liver transplantation: a randomized prospective multicenter trial. Gastroenterology 1996: 111: 710.
18. Lee SH, Rubin LJ. Current treatment strategies for pulmonary arterial hypertension. J Intern Med 2005: 258: 199.
19. Beirne C, Hynes N, Sultan S. Six years' experience with prostaglandin I2 infusion in elective open repair of abdominal aortic aneurysm: a parallel group observational study in a tertiary referral vascular center. Ann Vasc Surg 2008: 22: 750.
20. De Donato G, Gussoni G, De Donato G et al. The ILAILL study: iloprost as adjuvant to surgery for acute ischemia of lower limbs: a randomized, placebo-controlled, double-blind study by the Italian Society for Vascular and Endovascular Surgery. Ann Surg 2006: 244: 185.
21. Saghaei M. Random allocation software for parallel group randomized trials. BMC Med Res Methodol 2004: 4: 26.
22. Haller GW, Langrehr JM, Blumhardt G et al. Factors relevant to the development of primary dysfunction in liver allografts. Transplant Proc 1995: 27: 1192.
23. Pokorny H, Langer F, Herkner H et al. Influence of cumulative number of marginal donor criteria on primary organ dysfunction in liver recipients. Clin Transplant 2005: 19: 532.
24. Cameron AM, Ghobrial RM, Yersiz H et al. Optimal utilization of donor grafts with extended criteria: a single-center experience in over 1000 liver transplants. Ann Surg 2006: 243: 748. discussion 53-5.
25. Olthoff KM, Kulik L, Samstein B et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl 2010: 16: 943.
26. Chan MT, Gin T, Chui AK, Lau WY. Pitfalls of indocyanine green dye elimination to assess graft function during liver transplantation. Anesth Analg 2003: 96: 1839. author reply 40-1.
27. Bruegger L, Studer P, Schmid SW et al. Indocyanine green plasma disappearance rate during the anhepatic phase of orthotopic liver transplantation. J Gastrointest Surg 2008: 12: 67.
28. Stehr A, Ploner F, Traeger K et al. Plasma disappearance of indocyanine green: a marker for excretory liver function? Intensive Care Med 2005: 31: 1719.
29. Stockmann M, Malinowski M, Lock JF, Seehofer D, Neuhaus P. Factors influencing the indocyanine green (ICG) test: additional impact of acute cholestasis. Hepatogastroenterology 2009: 56: 734.
30. Cui Y, Konig J, Leier I, Buchholz U, Keppler D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 2001: 276: 9626.
31. Briceno J, Marchal T, Padillo J, Solorzano G, Pera C. Influence of marginal donors on liver preservation injury. Transplantation 2002: 74: 522.
32. Silberhumer GR, Pokorny H, Hetz H et al. Combination of extended donor criteria and changes in the Model for End-Stage Liver Disease score predict patient survival and primary dysfunction in liver transplantation: a retrospective analysis. Transplantation 2007: 83: 588.
33. Heise M, Settmacher U, Pfitzmann R et al. A survival-based scoring-system for initial graft function following orthotopic liver transplantation. Transpl Int 2003: 16: 794.
34. Nanashima A, Pillay P, Verran DJ et al. Analysis of initial poor graft function after orthotopic liver transplantation: experience of an Australian single liver transplantation center. Transplant Proc 2002: 34: 1231.
35. Riediger C, Muller MW, Michalski CW et al. T-Tube or no T-tube in the reconstruction of the biliary tract during orthotopic liver transplantation: systematic review and meta-analysis. Liver Transpl 2010: 16: 705.
36. Zardi EM, Picardi A, Ambrosino G, Serio A, Costantino S, Dobrina A. Hemodynamic effects of a prostacyclin analog (iloprost) on portal flow velocity and volume and visceral artery circulation in patients with lower limb arteriopathy. Ultrasound Med Biol 2003: 29: 209.
37. Zardi EM, Picardi A, Ambrosino G et al. Enhanced portal flow velocity and volume following Iloprost treatment. Acta Biomed 2003: 74(Suppl 2): 108.
38. Zardi EM, Picardi A, Ambrosino G et al. Iloprost enhances portal flow velocity and volume in patients with systemic sclerosis. In Vivo 2006: 20: 377.
39. Pascher A, Neuhaus P. Biliary complications after deceased-donor orthotopic liver transplantation. J Hepatobiliary Pancreat Surg 2006: 13: 487.
40. Buis CI, Hoekstra H, Verdonk RC, Porte RJ. Causes and consequences of ischemic-type biliary lesions after liver transplantation. J Hepatobiliary Pancreat Surg 2006: 13: 517.
41. Rocha PN, Carvalho EM. Prostanoids modulate inflammation and alloimmune responses during graft rejection. Braz J Med Biol Res 2005: 38: 1759.
42. Rauchfuss F, Scheuerlein H, Ludewig S, Uberruck T, Zanow J, Settmacher U. Prostaglandin application improves macro- and microcirculation after aorto-hepato-mesenteric bypass in chronic mesenteric ischemia. Clin Hemorheol Microcirc 2009: 43: 269.
43. Klein M, Geoghegan J, Wangemann R, Bockler D, Schmidt K, Scheele J. Preconditioning of donor livers with prostaglandin I2 before retrieval decreases hepatocellular ischemia-reperfusion injury. Transplantation 1999: 67: 1128.
44. Kotsch K, Ulrich F, Reutzel-Selke A et al. Methylprednisolone therapy in deceased donors reduces inflammation in the donor liver and improves outcome after liver transplantation: a prospective randomized controlled trial. Ann Surg 2008: 248: 1042.
45. Aggarwal S, Kang Y, Freeman JA, Fortunato FL Jr, Pinsky MR. Postreperfusion syndrome: hypotension after reperfusion of the transplanted liver. J Crit Care 1993: 8: 154.
46. Paugam-Burtz C, Kavafyan J, Merckx P et al. Postreperfusion syndrome during liver transplantation for cirrhosis: outcome and predictors. Liver Transpl 2009: 15: 522.
47. Moreno C, Sabate A, Figueras J et al. Hemodynamic profile and tissular oxygenation in orthotopic liver transplantation: influence of hepatic artery or portal vein revascularization of the graft. Liver Transpl 2006: 12: 1607.
48. Girn HR, Ahilathirunayagam S, Mavor AI, Homer-Vanniasinkam S. Reperfusion syndrome: cellular mechanisms of microvascular dysfunction and potential therapeutic strategies. Vasc Endovascular Surg 2007: 41: 277.
49. Olschewski H, Ghofrani HA, Walmrath D et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999: 160: 600.
50. Birnbaum J, Spies CD, Klotz E et al. Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study. Ren Fail 2007: 29: 271.
51. Palatianos GM, Foroulis CN, Vassili MI et al. Preoperative detection and management of immune heparin-induced thrombocytopenia in patients undergoing heart surgery with iloprost. J Thorac Cardiovasc Surg 2004: 127: 548.
52. Biggins SW, Beldecos A, Rabkin JM, Rosen HR. Retransplantation for hepatic allograft failure: prognostic modeling and ethical considerations. Liver Transpl 2002: 8: 313.
53. Kurokawa T, Nonami T, Harada A et al. Effects of prostaglandin E1 on the recovery of ischemia-induced liver mitochondrial dysfunction in rats with cirrhosis. Scand J Gastroenterol 1991: 26: 269.
54. Neumann UP, Kaisers U, Langrehr JM et al. Reduction of reperfusion injury with prostacyclin I2 after liver transplantation. Transplant Proc 1999: 31: 1029.
55. Giostra E, Chen H, Deng H et al. Prophylactic administration of prostaglandin E1 in liver transplantation: results of a pilot trial. Transplant Proc 1997: 29: 2381.
56. Henley KS, Lucey MR, Normolle DP et al. A double-blind, randomized, placebo-controlled trial of prostaglandin E1 in liver transplantation. Hepatology 1995: 21: 366.